

Bruno Imbimbo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2551447/publications.pdf>

Version: 2024-02-01

222
papers

10,471
citations

26567

56
h-index

42291

92
g-index

236
all docs

236
docs citations

236
times ranked

11646
citing authors

#	ARTICLE	IF	CITATIONS
1	A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. <i>Alzheimer's and Dementia</i> , 2022, 18, 1008-1037.	0.4	29
2	The β -Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 745-756.	0.7	336
3	Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 325-337.	0.9	2
4	Brain Amyloid Deposition in Late-Life Depression. <i>Biological Psychiatry</i> , 2021, 89, e41-e42.	0.7	3
5	Accelerating Alzheimer's disease drug discovery and development: what's the way forward?. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 727-735.	2.5	9
6	Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. <i>Journal of Affective Disorders</i> , 2021, 286, 275-281.	2.0	9
7	Can platelet activation result in increased plasma $A\beta$ levels and contribute to the pathogenesis of Alzheimer's disease?. <i>Ageing Research Reviews</i> , 2021, 71, 101420.	5.0	15
8	Can Anti- β -amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?. <i>Neurology: Genetics</i> , 2021, 7, e535.	0.9	10
9	What have we learned from past failures of investigational drugs for Alzheimer's disease?. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1175-1182.	1.9	13
10	Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 919-933.	1.9	22
11	Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer's disease or should they be looking elsewhere?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1241-1251.	2.5	15
12	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 213-228.	4.9	73
13	Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12004.	1.8	7
14	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 456.	2.2	201
15	Drug-induced reductions in brain amyloid- β levels may adversely affect cognition and behavior by a disruption of functional connectivity homeostasis. <i>Neurodegenerative Disease Management</i> , 2019, 9, 189-191.	1.2	1
16	Investigational BACE inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 967-975.	1.9	94
17	Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin. <i>Journal of Structural Biology</i> , 2019, 208, 165-173.	1.3	11
18	Time to test antibacterial therapy in Alzheimer's disease. <i>Brain</i> , 2019, 142, 2905-2929.	3.7	89

#	ARTICLE	IF	CITATIONS
19	Do anti-amyloid- β^2 drugs affect neuropsychiatric status in Alzheimer's disease patients?. <i>Ageing Research Reviews</i> , 2019, 55, 100948.	5.0	24
20	Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 599-602.	1.4	32
21	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1091-1107.	0.9	15
22	Disease-modifying therapies for tauopathies: agents in the pipeline. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 397-408.	1.4	15
23	A critical appraisal of amyloid- β^2 -targeting therapies for Alzheimer's disease. <i>Nature Reviews Neurology</i> , 2019, 15, 73-88.	4.9	666
24	Are antibodies directed against amyloid- β^2 (A β^2) oligomers the last call for the A β^2 hypothesis of Alzheimer's disease?. <i>Immunotherapy</i> , 2019, 11, 3-6.	1.0	50
25	Amyloid- β^2 immunotherapy for Alzheimer disease: Is it now a long shot?. <i>Annals of Neurology</i> , 2019, 85, 303-315.	2.8	126
26	Amyloid deposition in a mouse model humanized at the transthyretin and retinol-binding protein 4 loci. <i>Laboratory Investigation</i> , 2018, 98, 512-524.	1.7	6
27	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	1.4	34
28	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 847-857.	1.4	66
29	Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 989-1000.	1.2	42
30	CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 42-51.	1.4	13
31	Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 121-130.	1.2	41
32	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 89.e1-89.e8.	1.2	126
33	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 815-849.	1.2	249
34	Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation. <i>International Journal of Molecular Sciences</i> , 2017, 18, 184.	1.8	6
35	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. <i>BioMed Research International</i> , 2016, 2016, 1-15.	0.9	138
36	Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?. <i>International Psychogeriatrics</i> , 2016, 28, 1111-1124.	0.6	19

#	ARTICLE	IF	CITATIONS
37	Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 973-979.	1.2	23
38	Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 377-391.	1.0	54
39	Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. <i>Immunotherapy</i> , 2016, 8, 1119-1134.	1.0	61
40	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 259-277.	1.4	35
41	Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 457-461.	0.9	17
42	Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 889-899.	1.2	51
43	Alternative pharmacological treatment options for agitation in Alzheimer's disease. <i>Geriatric Care</i> , 2015, 1, .	0.2	1
44	Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 113.	1.7	67
45	CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. <i>Neuroscience</i> , 2015, 302, 112-120.	1.1	39
46	CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinoid-binding protein loci. <i>FEBS Letters</i> , 2015, 589, 849-856.	1.3	14
47	Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2581-2588.	0.9	43
48	Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 973-986.	1.4	42
49	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 405-419.	1.3	86
50	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. <i>Current Opinion in Psychiatry</i> , 2014, 27, 128-137.	3.1	86
51	Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1465-1476.	1.4	63
52	CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. <i>Neuroscience</i> , 2014, 266, 13-22.	1.1	8
53	Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia. <i>Pharmacological Research</i> , 2014, 81, 83-90.	3.1	22
54	Pharmacological targeting of the β -amyloid precursor protein intracellular domain. <i>Scientific Reports</i> , 2014, 4, 4618.	1.6	19

#	ARTICLE	IF	CITATIONS
55	Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. <i>BMC Neuroscience</i> , 2013, 14, 44.	0.8	58
56	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. <i>Age</i> , 2013, 35, 441-453.	3.0	35
57	Receptor for Advanced Glycation End Products Contributes to Postnatal Pulmonary Development and Adult Lung Maintenance Program in Mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 48, 164-171.	1.4	32
58	Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors. <i>FEBS Letters</i> , 2013, 587, 2325-2331.	1.3	21
59	O3-06-05: Sustained cognitive benefit in patients with mild cognitive impairment (MCI) upon prolonged treatment with CHF5074. , 2013, 9, P530-P530.		2
60	Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging. <i>Alzheimer's and Dementia</i> , 2013, 9, 113-122.	0.4	140
61	Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 278-286.	0.6	34
62	<scp>CHF</scp>5074 restores visual memory ability and preâ€synaptic cortical acetylcholine release in preâ€plaque Tg2576 mice. <i>Journal of Neurochemistry</i> , 2013, 124, 613-620.	2.1	16
63	Î³-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease?. <i>International Journal of Alzheimer's Disease</i> , 2013, 2013, 1-2.	1.1	1
64	CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study. <i>Current Alzheimer Research</i> , 2013, 10, 742-753.	0.7	73
65	Therapeutic effect of CHF5074, a new Î³-secretase modulator, in a mouse model of scrapie. <i>Prion</i> , 2012, 6, 62-72.	0.9	11
66	Immunotherapy for Alzheimerâ€™s disease: from anti-Î²-amyloid to tau-based immunization strategies. <i>Immunotherapy</i> , 2012, 4, 213-238.	1.0	121
67	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimerâ€™s disease patients. <i>Future Neurology</i> , 2012, 7, 395-401.	0.9	1
68	Advances in the identification of Î³-secretase inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 19-37.	2.5	45
69	Solanezumab for the treatment of mild-to-moderate Alzheimerâ€™s disease. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 135-149.	1.3	79
70	Metabolic-Cognitive Syndrome: Metabolic Approach for the Management of Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2012, 30, S1-S4.	1.2	10
71	Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1218-1238.	1.3	90
72	Monoclonal antibodies against Î²-amyloid (AÎ²) for the treatment of Alzheimer's disease: the AÎ² target at a crossroads. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 679-686.	1.4	40

#	ARTICLE	IF	CITATIONS
73	Therapeutic intervention for Alzheimer's disease with β -secretase inhibitors: still a viable option?. Expert Opinion on Investigational Drugs, 2011, 20, 325-341.	1.9	86
74	Gerontechnology for Demented Patients: Smart Homes for Smart Aging. Journal of Alzheimer's Disease, 2011, 23, 143-146.	1.2	48
75	Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert Review of Neurotherapeutics, 2011, 11, 677-708.	1.4	231
76	β -Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes. Current Topics in Medicinal Chemistry, 2011, 11, 1555-1570.	1.0	168
77	Mediterranean Diet in Predementia and Dementia Syndromes. Current Alzheimer Research, 2011, 8, 520-542.	0.7	73
78	The β -Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice. Journal of Alzheimer's Disease, 2011, 24, 799-816.	1.2	53
79	Comparison of Pharmacological Modulation of APP Metabolism in Primary Chicken Telencephalic Neurons and in a Human Neuroglioma Cell Line. Journal of Molecular Neuroscience, 2011, 43, 257-267.	1.1	14
80	The β -Secretase Modulator CHF5074 Reduces the Accumulation of Native Hyperphosphorylated Tau in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Molecular Neuroscience, 2011, 45, 22-31.	1.1	25
81	Metabolic Syndrome, Mild Cognitive Impairment and Dementia. Current Alzheimer Research, 2011, 8, 492-509.	0.7	67
82	Anti- β -Amyloid Immunotherapy for Alzheimer's Disease: Focus on Bapineuzumab. Current Alzheimer Research, 2011, 8, 808-817.	0.7	51
83	Interacting with β -Secretase for Treating Alzheimer's Disease: From Inhibition to Modulation. Current Medicinal Chemistry, 2011, 18, 5430-5447.	1.2	26
84	β -secretase inhibitors for treating Alzheimer's disease: rationale and clinical data. Clinical Investigation, 2011, 1, 1175-1194.	0.0	2
85	Aluminium in the Diet, Cognitive Decline and Dementia. , 2011, , 2829-2850.		0
86	Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms. Journal of Alzheimer's Disease, 2010, 21, 691-724.	1.2	139
87	Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	1.2	78
88	Nutraceutical Properties of Mediterranean Diet and Cognitive Decline: Possible Underlying Mechanisms. Journal of Alzheimer's Disease, 2010, 22, 715-740.	1.2	149
89	CHF5074, a Novel β -Secretase Modulator, Restores Hippocampal Neurogenesis Potential and Reverses Contextual Memory Deficit in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 159-173.	1.2	71
90	Peripheral Antioxidant Markers in Mild Cognitive Impairment and its Progression to Dementia. Journal of Alzheimer's Disease, 2010, 21, 1179-1183.	1.2	6

#	ARTICLE	IF	CITATIONS
91	Dietary Unsaturated Fatty Acids and Risk of Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 867-870.	1.2	12
92	Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	1.7	119
93	Are β -secretase inhibitors detrimental for Alzheimer's disease patients?. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 401-404.	1.2	10
94	Bapineuzumab: anti- β -amyloid monoclonal antibodies for the treatment of Alzheimer's disease. <i>Immunotherapy</i> , 2010, 2, 767-782.	1.0	52
95	Towards Disease-Modifying Treatment of Alzheimer's Disease: Drugs Targeting β -Amyloid. <i>Current Alzheimer Research</i> , 2010, 7, 40-55.	0.7	109
96	Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 98-116.	0.6	502
97	Polymorphisms in Glutathione S-Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease. <i>Rejuvenation Research</i> , 2010, 13, 645-652.	0.9	23
98	Interleukin 6 ϵ 174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 177-182.	2.5	27
99	REVIEW: β -Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 272-284.	1.9	63
100	Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 57-63.	1.2	69
101	Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treatment. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 17-30.	1.2	42
102	Polyunsaturated Fatty Acid and S-Adenosylmethionine Supplementation in Predementia Syndromes and Alzheimer's Disease: A Review. <i>Scientific World Journal</i> , The, 2009, 9, 373-389.	0.8	24
103	An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1147-1168.	1.9	88
104	Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. <i>Medicinal Research Reviews</i> , 2009, 29, 867-902.	5.0	35
105	CHF5074, a novel β -secretase modulator, attenuates brain β -amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2009, 156, 982-993.	2.7	83
106	Why Did Tarenflurbil Fail in Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 757-760.	1.2	65
107	Disease-Modifying Approach to the Treatment of Alzheimer's Disease. <i>Drugs and Aging</i> , 2009, 26, 537-555.	1.3	80
108	Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: drugs targeting β -amyloid and tau protein. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 386-406.	1.4	47

#	ARTICLE	IF	CITATIONS
109	Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 721-30.	2.3	9
110	Alzheimer's disease: β -secretase inhibitors. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2008, 5, 169-175.	0.5	22
111	Editorial [Hot Topic:Gamma-Secretase Inhibitors and Modulators as a Therapeutic Approach to Alzheimers disease (Guest Editor: Bruno P. Imbimbo)]. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 1-1.	1.0	1
112	Therapeutic Potential of β -Secretase Inhibitors and Modulators. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 54-61.	1.0	136
113	Conformation-sensitive Antibodies against Alzheimer Amyloid- β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide. <i>Journal of Biological Chemistry</i> , 2007, 282, 11436-11445.	1.6	66
114	1-(3,4-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel β -Secretase Modulator, Reduces Brain β -Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 822-830.	1.3	82
115	Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 2). <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1693-1697.	2.9	14
116	Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 1). <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1571-1583.	2.9	23
117	In vitro and in vivo profiling of CHF5022 and CHF5074. <i>Pharmacological Research</i> , 2007, 55, 318-328.	3.1	42
118	CHF3381, a N-methyl-D-aspartate Receptor Antagonist and Monoamine Oxidase-A Inhibitor, Attenuates Secondary Hyperalgesia in a Human Pain Model. <i>Journal of Pain</i> , 2006, 7, 565-574.	0.7	33
119	Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β -Amyloid1-42 Secretion. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5705-5720.	2.9	120
120	Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 405-414.	1.1	5
121	Mechanistic Pharmacokinetic and Pharmacodynamic Modeling of CHF3381 (2-[(2,3-Dihydro-1H-inden-2-yl)amino]acetamide Monohydrochloride), a Novel N-Methyl-d-aspartate Antagonist and Monoamine Oxidase-A Inhibitor in Healthy Subjects. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 647-657.	1.3	3
122	Pathophysiology of Alzheimer's Disease. <i>Neuroimaging Clinics of North America</i> , 2005, 15, 727-753.	0.5	68
123	Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2004, 19, 153-160.	0.9	22
124	The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1469-1481.	1.9	51
125	P4-342 High throughput screening of β -amyloid secretion inhibitors using homogenous time-resolved fluorescence. <i>Neurobiology of Aging</i> , 2004, 25, S572.	1.5	0
126	O3-06-05 New flurbiprofen analogues, devoid of cyclooxygenase activity, selectively lower β -amyloid1-42 secretion. <i>Neurobiology of Aging</i> , 2004, 25, S64-S65.	1.5	0

#	ARTICLE	IF	CITATIONS
127	High Throughput Screening of β -Amyloid Secretion Inhibitors Using Homogenous Time-Resolved Fluorescence. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2004, 7, 745-756.	0.6	3
128	The protective effect of ganstigmine against amyloid β 25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition. <i>Neuroscience Letters</i> , 2003, 341, 181-184.	1.0	15
129	Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N-Methyl-D-Aspartate Antagonist, after Single Oral Doses in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 901-911.	1.0	8
130	Toxicity of β -amyloid vaccination in patients with Alzheimer's disease. <i>Annals of Neurology</i> , 2002, 51, 794-794.	2.8	57
131	β -Amyloid immunization approaches for Alzheimer's disease. <i>Drug Development Research</i> , 2002, 56, 150-162.	1.4	8
132	Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer's Disease. <i>CNS Drugs</i> , 2001, 15, 375-390.	2.7	109
133	Central acetylcholinesterase inhibition in Alzheimer patients. <i>Annals of Neurology</i> , 2001, 49, 416-416.	2.8	0
134	Synthesis of New Cardioselective M2 Muscarinic Receptor Antagonists.. <i>Chemical and Pharmaceutical Bulletin</i> , 2000, 48, 1611-1622.	0.6	10
135	A 6-Month, Double-Blind, Placebo-Controlled Trial of Eptastigmine in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 17-24.	0.7	18
136	Hemodynamic effects of MF 10058, a new cardioselective muscarinic M2 receptor antagonist, in conscious dogs. <i>European Journal of Pharmacology</i> , 2000, 406, 93-98.	1.7	3
137	PHARMACODYNAMICS OF A LONG ACTING DEPOT PREPARATION OF AVORELIN IN PATIENTS WITH PROSTATE CANCER. <i>Journal of Urology</i> , 1999, 162, 2019-2023.	0.2	9
138	Two-Year Treatment of Alzheimer's Disease with Eptastigmine. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 139-147.	0.7	35
139	Suicide in Two Patients with a Diagnosis of Probable Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 1999, 13, 88-90.	0.6	33
140	Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. <i>Neurology</i> , 1999, 52, 700-700.	1.5	44
141	Effect of food on the absorption of eptastigmine. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 243-247.	0.8	5
142	Acetylcholinesterase assay may predict cognitive response of Alzheimer patients to eptastigmine treatment. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 809-810.	0.8	1
143	Lack of effect of hexarelin on TRH-induced TSH response in normal adult man. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 239-244.	1.8	1
144	Cardiac Autonomic Dysfunction in Patients with Alzheimer Disease: Possible Pathogenetic Mechanisms. <i>Alzheimer Disease and Associated Disorders</i> , 1998, 12, 356-361.	0.6	44

#	ARTICLE	IF	CITATIONS
145	A 25-Week Placebo-Controlled Study of Eptastigmine in Patients with Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 1998, 12, 313-322.	0.6	18
146	Maximum Tolerated Dose and Pharmacodynamics of Eptastigmine in Elderly Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 610-617.	1.0	20
147	Population pharmacokinetics of rufloxacin in patients with acute exacerbations of chronic bronchitis. <i>European Journal of Pharmaceutical Sciences</i> , 1997, 5, 37-42.	1.9	2
148	The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. <i>Respiratory Medicine</i> , 1997, 91, 449-460.	1.3	22
149	Acute administration of hexarelin stimulates GH secretion during day and night in normal men. <i>Clinical Endocrinology</i> , 1997, 46, 275-279.	1.2	2
150	Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer's Disease. , 1997, , 223-230.		4
151	Pharmacodynamic monitoring of eptastigmine in capillary blood. <i>European Journal of Clinical Pharmacology</i> , 1996, 50, 425-427.	0.8	4
152	Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 218-228.	2.3	60
153	A Patient-Side Technique for Real-Time Measurement of Acetylcholinesterase Activity During Monitoring of Eptastigmine Treatment. <i>Therapeutic Drug Monitoring</i> , 1995, 17, 230-238.	1.0	14
154	Relationship Between Pharmacokinetics and Pharmacodynamics of Eptastigmine in Young Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 285-290.	1.0	26
155	Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. <i>Endocrine Research</i> , 1995, 21, 569-582.	0.6	3
156	Modulation of Growth Hormone-Releasing Activity of Hexarelin in Man. <i>Neuroendocrinology</i> , 1995, 61, 51-56.	1.2	71
157	The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 2692-2696.	1.8	28
158	Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 1090-1094.	1.8	40
159	Mechanism of Action of Hexarelin and GHRP-6: Analysis of the Involvement of GHRH and Somatostatin in the Rat. <i>Neuroendocrinology</i> , 1995, 61, 44-50.	1.2	56
160	Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. <i>Journal of Endocrinology</i> , 1995, 146, 227-232.	1.2	36
161	The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 674-678.	1.8	36
162	Hexarelin, a potent GHRP analogue: Interactions with GHRH and clonidine in young and aged dogs. <i>Peptides</i> , 1995, 16, 81-86.	1.2	26

#	ARTICLE	IF	CITATIONS
163	Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 134-138.	1.5	56
164	The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 674-678.	1.8	29
165	Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 1090-1094.	1.8	35
166	The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 2692-2696.	1.8	26
167	Growth hormone-releasing activity of hexarelin in humans. <i>European Journal of Clinical Pharmacology</i> , 1994, 46, 421-5.	0.8	55
168	Distension-stimulated propagated contractions in human colon. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1955-1960.	1.1	60
169	Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 693-698.	1.8	144
170	Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 693-698.	1.8	110
171	Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1440-1443.	1.8	59
172	Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis. <i>Hepatology</i> , 1993, 18, 847-852.	3.6	8
173	Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. <i>European Journal of Clinical Pharmacology</i> , 1993, 45, 373-6.	0.8	16
174	Prolonged Effects of Cholinesterase Inhibition with Eptastigmine on the Cerebral Blood Flow-Metabolism Ratio of Normal Rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 702-711.	2.4	25
175	Impaired colonic motor response to cholinergic stimulation in patients with severe chronic idiopathic (slow transit type) constipation. <i>Digestive Diseases and Sciences</i> , 1993, 38, 1040-1045.	1.1	87
176	Rapid potentiometric determination of cholinesterases in plasma and red cells: Application to eptastigmine monitoring. <i>Chemico-Biological Interactions</i> , 1993, 87, 265-268.	1.7	6
177	Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases. <i>European Journal of Clinical Pharmacology</i> , 1993, 45, S29-S34.	0.8	12
178	Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs. <i>Life Sciences</i> , 1993, 53, 389-395.	2.0	3
179	The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure.. <i>British Journal of Clinical Pharmacology</i> , 1993, 35, 335-339.	1.1	4
180	Pharmacokinetics of rufloxacin in patients with impaired renal function. <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 637-641.	1.4	15

#	ARTICLE	IF	CITATIONS
181	Biliary excretion of rufloxacin in humans. <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 2545-2549.	1.4	8
182	The penetration of rufloxacin into sites of potential infection in the respiratory tract. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 32, 861-866.	1.3	22
183	Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 2212-2216.	1.4	24
184	Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36, 1296-1301.	1.4	35
185	Steady-State Pharmacokinetics of Rufloxacin in Elderly Patients with Lower Respiratory Tract Infections. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 36-41.	1.0	18
186	High-performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites, N-desmethylrufloxacin and rufloxacin sulfoxide, in urine of Rhesus monkey <i>Macaca mulatta</i> . <i>Biomedical Applications</i> , 1992, 573, 168-172.	1.7	7
187	059 Preliminary data on heptastigmine monitoring. <i>Fresenius' Journal of Analytical Chemistry</i> , 1992, 343, 115-115.	1.5	0
188	Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms. <i>Digestive Diseases and Sciences</i> , 1992, 37, 262-267.	1.1	42
189	High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacin sulfoxide in plasma and urine of humans. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1992, 17, 45-49.	0.6	8
190	Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections. <i>Infection</i> , 1992, 20, 89-93.	2.3	9
191	Pharmacokinetics of Rufloxacin in Healthy Volunteers after Repeated Oral Doses. <i>Chemotherapy</i> , 1991, 37, 389-397.	0.8	21
192	Edrophonium chloride for testing colonic contractile activity in man. <i>Acta Physiologica Scandinavica</i> , 1991, 141, 289-293.	2.3	19
193	Efficiency of different criteria for selecting pharmacokinetic multiexponential equations. <i>Biopharmaceutics and Drug Disposition</i> , 1991, 12, 139-147.	1.1	29
194	Kinetics of cholinesterase inhibition by eptastigmine in man. <i>European Journal of Clinical Pharmacology</i> , 1991, 41, 83-84.	0.8	33
195	Inter- and intraindividual variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 1991, 35, 390-393.	1.4	52
196	Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. <i>Journal of Antimicrobial Chemotherapy</i> , 1991, 28, 905-909.	1.3	37
197	Effects of cimetropium bromide on gallbladder contraction in response to oral and intraduodenal olive oil. <i>European Journal of Clinical Pharmacology</i> , 1990, 39, 369-372.	0.8	4
198	Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. <i>Gut</i> , 1990, 31, 355-358.	6.1	59

#	ARTICLE	IF	CITATIONS
199	Bone loss in response to long-term glucocorticoid therapy. <i>Bone and Mineral</i> , 1990, 8, 39-51.	2.0	339
200	New Glucocorticoids. Mechanisms of Immunological Activity at the Cellular Level and in the Clinical Setting. <i>Annals of the New York Academy of Sciences</i> , 1990, 595, 368-382.	1.8	29
201	Inhibition of acetylcholinestense and butyrylcholinesterase after oral administration of heptastigmine in healthy volunteers. <i>European Journal of Pharmacology</i> , 1990, 183, 536.	1.7	4
202	Inhibition of caerulein-induced gall bladder emptying by cimetropium bromide in humans. <i>European Journal of Clinical Pharmacology</i> , 1989, 37, 483-486.	0.8	3
203	Comparative Study of the Effects of Cimetropium Bromide and Atropine on Human Esophageal Motor Functions. <i>Digestion</i> , 1989, 44, 117-123.	1.2	8
204	Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1989, 3, 267-276.	1.9	24
205	A New Criterion for Selection of Pharmacokinetic Multiexponential Equations. <i>Journal of Pharmaceutical Sciences</i> , 1988, 77, 784-789.	1.6	35
206	Effect of mifentidine on peptone meal-stimulated gastric acid secretion and plasma gastrin levels in duodenal ulcer patients. <i>Agents and Actions</i> , 1988, 25, 22-26.	0.7	4
207	Safety and pharmacokinetics of mifentidine after increasing oral doses in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 1988, 35, 673-676.	0.8	1
208	Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome. <i>European Journal of Clinical Pharmacology</i> , 1988, 33, 571-575.	0.8	13
209	Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 407-413.	1.1	5
210	Gastric Acid and Pepsin Secretion after Single Oral Doses of Mifentidine in Healthy Subjects. <i>Scandinavian Journal of Gastroenterology</i> , 1988, 23, 788-792.	0.6	2
211	Manometric Evaluation of Cimetropium Bromide Activity in Patients with the Nutcracker Oesophagus. <i>Scandinavian Journal of Gastroenterology</i> , 1988, 23, 1079-1084.	0.6	23
212	Efficacy of cimetropium bromide as pre-medication for double-contrast barium enema. <i>British Journal of Radiology</i> , 1988, 61, 1087-1088.	1.0	2
213	Colonic mass movements in idiopathic chronic constipation.. <i>Gut</i> , 1988, 29, 1173-1179.	6.1	227
214	Transverse and Sigmoid Colon Motility in Healthy Humans: Effects of Eating and of Cimetropium Bromide. <i>Digestion</i> , 1987, 37, 59-64.	1.2	46
215	Action of mifentidine on the secretory response to sham feeding and pentagastrin and on serum gastrin in duodenal ulcer patients. <i>European Journal of Clinical Pharmacology</i> , 1987, 32, 555-558.	0.8	8
216	Urinary excretion of cimetropium bromide after multiple oral doses. <i>European Journal of Clinical Pharmacology</i> , 1987, 33, 337-338.	0.8	3

#	ARTICLE	IF	CITATIONS
217	Effects of a new heterocyclic glucocorticoid, deflazacort (DFC), on the functions of lymphocytes from patients with rheumatoid arthritis (RA). <i>International Journal of Immunopharmacology</i> , 1987, 9, 133-139.	1.1	9
218	Effects of Pirenzepine and Atropine on Gastroduodenal Motor Patterns in Duodenal Ulcer Patients. <i>Scandinavian Journal of Gastroenterology</i> , 1986, 21, 1046-1050.	0.6	4
219	Discontinuous Oral Absorption of Cimetropium Bromide, a New Antispasmodic Drug. <i>Journal of Pharmaceutical Sciences</i> , 1986, 75, 680-684.	1.6	26
220	Cimetropium bromide as a relaxant for the radiological examination of the stomach and duodenum. <i>Current Medical Research and Opinion</i> , 1986, 10, 319-325.	0.9	6
221	The Use of Cimetropii Bromidum as Premedication for Endoscopy of the Upper Gastro-Intestinal Tract: A Double-Blind Controlled Clinical Trial. <i>Journal of International Medical Research</i> , 1985, 13, 332-337.	0.4	4
222	Effect of single oral doses of prednisone and deflazacort on human lymphocyte distribution and functions. Analysis with monoclonal antibodies. <i>Advances in Experimental Medicine and Biology</i> , 1984, 171, 335-44.	0.8	10